OncoSil Medical has received US Food and Drug Administration approval for its OncoSil device to treat patients with unresectable, non-metastatic distal cholangiocarcinoma, giving the Australian medical-device company a pathway into the world’s largest healthcare market.

Biotron is preparing to advance its hepatitis B drug candidate into formal preclinical development after new laboratory studies found it showed strong antiviral activity against both hepatitis B and hepatitis D viruses, including in combination with an existing treatment for hepatitis delta.

Six Australian health and medical technology startups have secured a combined $13.5 million through the second funding round of CUREator+, as the national commercialisation program seeks to move locally developed therapies, diagnostics and digital health tools closer to patients and private investment.

Perth biotechnology company Spartan Therapeutics says it plans to begin a human clinical trial in 2027 of a circular RNA platform designed to restore more youthful function in organs and tissues across the body.

CLINUVEL has identified a lead formulation from its VLRX L controlled-release injectable peptide platform and plans to progress it into further preclinical studies in the first quarter of 2027.

QIMR Berghofer researchers have created a detailed new map of the chemical signals that influence heart function, in a development that could help accelerate the discovery of new treatments for heart disease.

Starpharma has completed its fully underwritten $32 million entitlement offer, securing strong backing from existing shareholders as it prepares to advance its DEP HER2-Lutetium oncology program into first-in-human clinical testing.

AdAlta has reported continued survival among patients in its early-stage Chinese study of EW-001, with all five participants remaining alive at the company’s March update and still in follow-up as of July.

AusBiotech has unveiled the integrated program for the 2026 AusBiotech International Conference and AusMedtech Conference, bringing more than 250 speakers together across approximately 60 sessions on the Gold Coast in October.

Percheron Therapeutics, previously known as Antisense, has appointed biotech executive Dr Michael Baker as its new chief executive officer and managing director, as current CEO Dr James Garner prepares to leave the role for an overseas opportunity.

Neuren Pharmaceuticals has reported a record quarter for DAYBUE (trofinetide), with its partner, Acadia Pharmaceuticals, reporting net sales of US$125 million in the second quarter of 2026.

Clarity Pharmaceuticals has reported two additional complete responses among participants receiving its investigational radiopharmaceutical 67Cu-SAR-bisPSMA in the SECuRE trial, bringing the total number of complete responses or cases of undetectable disease across the company’s program to seven.

QIMR Berghofer and James Cook University have strengthened their strategic partnership to establish one of Australia’s leading collaborations in tropical health research, with a focus on accelerating the development of vaccines, diagnostics and therapeutics while preparing the next generation of health researchers.

A patient treated with a single dose of AdAlta’s experimental CAR T cell therapy EW 001 has remained free of cancer recurrence for two years, marking a significant milestone in the company’s ongoing mesothelioma study in China.

Amplia Therapeutics has entered into a clinical trial collaboration and supply agreement with Eli Lilly to evaluate whether its investigational FAK inhibitor narmafotinib can improve treatment outcomes when combined with Lilly’s next-generation KRAS G12C inhibitor olomorasib.

Neurizon Therapeutics has entered into a strategic research and development financing facility with the Dare Capital Loan Fund, providing up to $17.5 million in additional capital to support its work on treatments for neurodegenerative diseases.

Noxopharm has reported preclinical results showing that its technology can help the immune system recognise cellular RNA that would normally fail to trigger an anti-cancer response.